Publications

Mollenhauer, B, CJ Caspell-Garcia, CS Coffey, P Taylor, LM Shaw, JQ Trojanowski, A Singleton, et al. 2017. “Longitudinal CSF Biomarkers in Patients With Early Parkinson Disease and Healthy Controls. Neurology 2017;89:1959-1969.”. Neurology.

Schobel, SA, G Palermo, P Auinger, JD Long, S Ma, OS Khwaja, D Trundell, 2CARE Huntington Study Group Investigators, and . 2017. “Motor, Cognitive, and Functional Declines Contribute to a Single Progressive Factor in Early HD. Neurology 2017;89:2495-2502.”. Neurology.

Oertel, W, K Eggert, R Pahwa, CM Tanner, RA Hauser, C Trenkwalder, R Ehret, et al. 2017. “Randomized, Placebo-Controlled Trial of ADS-5102 (amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 3). Mov Disord 2017;32:1701-1709.”. Mov Disord.

Hauser, RA, R Pahwa, CM Tanner, W Oertel, SH Isaacson, R Johnson, L Felt, and MJ Stempien. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.”. J Parkinsons Dis.

Seeberger, LC, and RA Hauser. 2017. “Seeberger LC, Hauser RA.Valbenazine for the Treatment of Tardive Dyskinesia. Expert Opin Pharmacother 2017;18:1279-1287.”. Expert Opin Pharmacother.

Anderson, KE, D Stamler, MD Davis, SA Factor, RA Hauser, J Isojarvi, LF Jarskog, et al. 2017. “Deutetrabenazine for Treatment of Involuntary Movements in Patients With Tardive Dyskinesia (AIM-TD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Psychiatry 2017;4:595-604.”. Lancet Psychiatry.

Goetz, CG, GT Stebbins, KA Chung, AP Nicholas, RA Hauser, D Merkitch, and MA Stacy. 2017. “Topiramate As an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study. Mov Disord 2017;32:1335-1336.”. Mov Disord.

Pahwa, R, CM Tanner, RA Hauser, SH Isaacson, PA Nausieda, DD Truong, P Agarwal, et al. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.”. JAMA Neurol.

Biglan, KM, D Oakes, AE Lang, RA Hauser, K Hodgeman, B Greco, J Lowell, et al. 2017. “A Novel Design of a Phase III Trial of Isradipine in Early Parkinson Disease (STEADY-PD III). Ann Clin Transl Neurol 2017;4:360-368.”. Ann Clin Transl Neurol.

Tilley, BC, AG Mainous, DW Smith, MD McKee, RP Amorrortu, J Alvidrez, V Diaz, et al. 2017. “Design of a Cluster-Randomized Minority Recruitment Trial: RECRUIT. Clin Trials 2017;14:286-298.”. Clin Trials.